Biotech Rips Following Five-Year Master Service Agreement Release

There is something about biotech companies that seems to get everyone excited in the penny stock realm. Whether it’s the potential for major FDA approval announcements or the possibility of other key press headlines such as federal grants, those who monitor and trade biotechs never have a dull moment.

Scinai Immunotherapeutics Ltd. (Nasdaq:SCNI) did not break the trend on Monday after the company announced a five-year master service agreement to provide drug development and cGMP manufacturing services to Ayana Pharma. Shares of the micro cap traded pretty sporadically for a bit, but went on to close up at $0.49/share (+4.26%). 

BiondVax Pharmaceuticals Ltd is engaged in the healthcare sector. Its main activity is the commercialization and manufacturing of flu vaccine. Its product is designed to provide multi-season and multi-strain protection against some human influenza virus strains, including both seasonal and pandemic flu strains. The company recently concluded two Phase I/II trials in which the multimeric-001 universal flu vaccine was shown to be safe and immunogenic.

Copyright © 2024 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com’s content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

]]>